Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max Kates

Showing results (71-80 of 157) with videos related to

Pageof 16
Sort By:
World Journal of Urology|March 10, 2019
Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancerAaron Brant, Marcus Daniels, Meera R Chappidi, et al.
Urologic Oncology|November 19, 2013
In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United StatesMax Kates, Michael A Gorin, Christopher M Deibert, et al.
The Journal of Sexual Medicine|May 3, 2017
Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims DatabaseMeera R Chappidi, Max Kates, Nikolai A Sopko, et al.
BJU International|April 11, 2012
Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference?Gina M Badalato, Josep M Gaya, Gregory Hruby, et al.
The Canadian Journal of Urology|February 18, 2014
Impact of hospital volume on perioperative outcomes and costs of radical cystectomy: analysis of the Maryland Health Services Cost Review Commission databaseMichael A Gorin, Max Kates, Jeffrey K Mullins, et al.
BJU International|April 19, 2017
Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims databaseMeera R Chappidi, Max Kates, Jeffrey J Tosoian, et al.
British Journal of Cancer|October 18, 2018
CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancerAkira Ooki, Christopher J VandenBussche, Max Kates, et al.
European Urology|July 2, 2016
PSMA-Targeted <sup>18</sup>F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid AutopsyMichael A Gorin, Steven P Rowe, Jody E Hooper, et al.
Bladder Cancer (Amsterdam, Netherlands)|November 21, 2017
Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder CancerNiv Milbar, Max Kates, Meera R Chappidi, et al.
Urology|January 21, 2017
Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder CancerMeera R Chappidi, Max Kates, Aaron Brant, et al.
Pageof 16

Showing results (71-80 of 157) with videos related to

Sort By:
Pageof 16
World Journal of Urology|March 10, 2019
Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancerAaron Brant, Marcus Daniels, Meera R Chappidi, et al.
Urologic Oncology|November 19, 2013
In-hospital death and hospital-acquired complications among patients undergoing partial cystectomy for bladder cancer in the United StatesMax Kates, Michael A Gorin, Christopher M Deibert, et al.
The Journal of Sexual Medicine|May 3, 2017
Erectile Dysfunction Treatment Following Radical Cystoprostatectomy: Analysis of a Nationwide Insurance Claims DatabaseMeera R Chappidi, Max Kates, Nikolai A Sopko, et al.
BJU International|April 11, 2012
Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference?Gina M Badalato, Josep M Gaya, Gregory Hruby, et al.
The Canadian Journal of Urology|February 18, 2014
Impact of hospital volume on perioperative outcomes and costs of radical cystectomy: analysis of the Maryland Health Services Cost Review Commission databaseMichael A Gorin, Max Kates, Jeffrey K Mullins, et al.
BJU International|April 19, 2017
Evaluation of gender-based disparities in time from initial haematuria presentation to upper tract urothelial carcinoma diagnosis: analysis of a nationwide insurance claims databaseMeera R Chappidi, Max Kates, Jeffrey J Tosoian, et al.
British Journal of Cancer|October 18, 2018
CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancerAkira Ooki, Christopher J VandenBussche, Max Kates, et al.
European Urology|July 2, 2016
PSMA-Targeted <sup>18</sup>F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid AutopsyMichael A Gorin, Steven P Rowe, Jody E Hooper, et al.
Bladder Cancer (Amsterdam, Netherlands)|November 21, 2017
Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder CancerNiv Milbar, Max Kates, Meera R Chappidi, et al.
Urology|January 21, 2017
Assessing Cancer Progression and Stable Disease After Neoadjuvant Chemotherapy for Organ-confined Muscle-invasive Bladder CancerMeera R Chappidi, Max Kates, Aaron Brant, et al.
Pageof 16